

08/15/01

08-16-01

JC20 Rec'd PCT/PTO 15 AUG 2001

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK		ATTORNEY'S DOCKET NO. 1292 WO/US
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known see 37 CFR 1.5) 09/913788
INTERNATIONAL APPLICATION NO. PCT/EP00/01553	INTERNATIONAL FILING DATE 24 February, 2000	PRIORITY DATE CLAIMED 24 February, 1999
TITLE OF INVENTION COMBINATION OF INTERCALATING ORGANOMETALLIC COMPLEXES AND TUMOR SEEKING BIOMOLECULES FOR DNA CLEAVAGE AND RADIOTHERAPY		
APPLICANT(S) FOR DO/EO/US MALLINCKRODT INC.		
Applicant herewith submits to the United States Designed/Elected Office (DO/EO/US) the following items and other information: <ol style="list-style-type: none">1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))<ol style="list-style-type: none">a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371 (c)(2)).7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))<ol style="list-style-type: none">a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).b. <input checked="" type="checkbox"/> have been transmitted by the International Bureauc. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.d. <input type="checkbox"/> have not been made and will not be made.8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). Items 11. to 16. below concern document(s) or information included: <ol style="list-style-type: none">11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.13. <input checked="" type="checkbox"/> A FIRST preliminary amendment <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.14. <input type="checkbox"/> A substitute specification.15. <input checked="" type="checkbox"/> A change of power of attorney and/or address letter.16. <input type="checkbox"/> Other items or information.		

09/913788

PCT/EP00/01553

531 Rec'd PCT

15 AUG 2001

1292 WO/US

17. ☒ The following Fees are submitted:**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):**

Neither international preliminary examination fee (37 CFR 1.482)
 nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
 and International Search Report not prepared by the EPO or JPO.....\$1000.00
 International preliminary examination fee (37 CFR 1.482) not paid to
 USPTO but International Search Report prepared by the EPO or JPO.....\$860.00
 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but
 international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$710.00
 International preliminary examination fee paid to USPTO (37 CFR 1.482)
 but all claims did not satisfy provisions of PCT Article 33(1)-(4).....\$690.00
 International preliminary examination fee paid to USPTO (37 CFR 1.482)
 and all claims satisfied provisions of PCT Article 33 (1)-(4).....\$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =**\$860.00**

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30
 months from the earliest claimed priority date (37 CFR 1.492(e)).

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	24 - 20 =	4	x \$18.00
Independent claims	8 - 3 =	5	x \$78.00
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)			+ \$270.00

\$72.00**\$390.00****\$270.00****TOTAL OF ABOVE CALCULATIONS =****\$1592.00**

Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement
 must also be filed (Note 37 CFR 1.9, 1.27, 1.28).

\$0.00**SUBTOTAL =****\$1592.00**

Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30
 months from the earliest claimed priority date (37 CFR 1.492(f)).

\$0.00**TOTAL NATIONAL FEE =****\$1592.00**

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be
 accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **\$40.00** per property.
 +

\$40.00**TOTAL FEES ENCLOSED =****\$1632.00**

**Amount to be
 refunded:**

\$

charged:

\$

a. ☐ A check in the amount of \$ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 13-1160 in the amount of \$1178.00 to cover the above fees.
 A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
 overpayment to Deposit Account No. 13-1160. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Jeffrey S. Boone
 Mallinckrodt Inc.
 675 McDonnell Boulevard
 P.O. Box 5840
 St. Louis, Missouri 63134


 SIGNATURE

Jeffrey S. Boone

NAME

29,284

REGISTRATION NUMBER

09/913788
531 Rec'd PCT 15 AUG 2001
PATENT

<u>CERTIFICATE OF MAILING</u>	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, DC 20231 on or before the following date:	
Date	Paula E. Ruch

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

International Application No. PCT/EP00/01553

International Filing Date: 02/24/2000


Title: COMBINATION OF INTERCALATING ORGANOMETALLIC COMPLEXES
AND TUMOR SEEKING BIOMOLECULES FOR DNA CLEAVAGE AND
RADIOTHERAPY

Attorney Docket No.: 1292 WO/US

PRELIMINARY AMENDMENT

Please cancel any previous claims and replace with attached revised claims.

Respectfully submitted,



Jeffrey S. Boone, J.D.
Attorney for Applicant(s)
Registration No. 29,284

Mallinckrodt Inc.
675 McDonnell Boulevard
P.O. Box 5840
St. Louis, MO 63134
Telephone: (314) 654-8955
Fax: (314) 654-3156
August 6, 2001

09/913788

What is claimed is:

1. The use of molecules that are taken up by the cell, which molecules comprise a tumor seeking biomolecule coupled to an intercalating moiety, which is complexed to a metal, which metal is preferably a radioactive metal, for the preparation of a therapeutic composition for the treatment and diagnosis of tumors and malignancies.
2. The use as claimed in claim 1 wherein the biomolecule is selected from the group consisting of somatostatin-, neurotensin-, bombesin-receptor binding molecules, antibodies, penetratinesTM, and molecules binding to the GPIIb/IIIa receptors.
3. The use as claimed in claims 1 or 2 wherein the intercalating agent is an aromatic molecule with an intercalative binding affinity for double-stranded DNA.
4. The use as claimed in claim 3, wherein the intercalating agent is selected from the group consisting of acridine, porphyrin, ellipticine, phenantroline, carbazole, benzimidazole or compounds with known cytostatic activity (antibiotics) from the class of tetracyclines (anthracyclines), such as daunorubicine, epirubicine or mixoxantrone.
5. The use as claimed in claims 1 or 2, wherein the radioactive metal is a γ -emitting nuclide.
6. The use as claimed in claim 3, wherein the radioactive metal is a γ -emitting nuclide.
7. The use as claimed in claim 4, wherein the radioactive metal is a γ -emitting nuclide.

8. The use as claimed in claim 5, wherein the radioactive metal is selected from the group consisting of Tc-99m, Re-186, Re-188 and Mn.
9. The use as claimed in claim 1, wherein the molecule has the general structural formula as given in Fig. 2.
10. The use as claimed in claim 1, wherein the molecule has any one of the structures as shown in Fig. 1.
11. The use of molecules as claimed in claim 1 for the preparation of a therapeutic or diagnostic agent for treating or diagnosing cancer tumors or malignancies.
12. A therapeutic composition, comprising one or more molecules as claimed in claim 1 and one or more suitable excipients.
13. A diagnostic composition, comprising one or more molecules as claimed in claim 1 in a suitable carrier.
14. A compound comprising
- (a) a biomolecule molecule selected from somatostatin, neurotensin, bombesin-receptor binding molecules, antibodies, penetratinesTM, and molecules binding to GPIIb/IIIa receptors;
coupled to
 - (b) an aromatic intercalating moiety with binding affinity for double-stranded DNA selected from acridine, porphyrin, ellipticine, phenantroline, carbazole, benzimidazole, and tetracycline compounds with cytostatic activity;
which is complexed to
 - (c) a γ -emitting radioactive metal selected from Tc-99m, Re-186, Re-188, and Mn.

15. The use of the compound of claim 14 to diagnose a tumor.

16. The use of the compound of claim 14 to treat a tumor.

17. A kit for the preparation of a diagnostic or therapeutic composition comprising

(a) a biomolecule molecule selected from somatostatin, neurotensin, bombesin-receptor binding molecules, antibodies, penetratinesTM, and molecules binding to GPIIb/IIIa receptors;

coupled to

(b) an aromatic intercalating moiety with binding affinity for double-stranded DNA selected from acridine, porphyrin, ellipticine, phenantroline, carbazole, benzimidazole, and tetracycline compounds with cytostatic activity; and

(c) instructions to combine the above composition with a γ -emitting radioactive metal selected from Tc-99m, Re-186, Re-188, and Mn.

18. The kit of claim 17 additionally including one or more pharmaceutically acceptable excipients.

MOLECULES FOR THE TREATMENT AND DIAGNOSIS OF TUMOURS

The present invention relates to new molecules for the treatment and diagnosis of tumors. The invention furthermore relates to therapeutical compositions comprising one or more of these molecules and to the use
5 of both in treatment and diagnosis of cancer.

The diagnosis and therapy of cancer still requires a large input from the pharmaceutical and chemical industry. Although a substantial effort is made to develop new treatments, there are still many tumor
10 types for which no treatment exists. An additional problem is the formation of micrometastases, which cannot be diagnosed or treated.

An important problem in treatment is the similarity between normal cells and cancer cells.
15 Treatments interfering with the growth of tumor cells will also interfere in the growth of healthy cells. Radiotherapy as it is now known consists essentially of an arbitrary cross-fire from outside the cell or the cytoplasm. Because this is a rather rough treatment
20 surrounding cells and tissues might also be damaged leading to more or less severe side effects.

The provision of an improved radiotherapy and diagnostic method for cancer which uses very low amounts of radionuclides and leads to a direct treatment in the
25 malignant cell is therefore highly desirable.

It is known that the metabolism of cancer cells differs from that of normal cells. In addition, cancer cells appear to have an increased membrane permeability in comparison to normal cells due to an increased
30 expression of membrane receptors. The result is that the cancer cells are more permeable for biological vectors, like proteins and peptides.

The enhanced uptake of such biological vectors can be used in the diagnosis of tumors by binding a

09/913788-081501

radionuclide to a protein, for example by iodination of tyrosine functions in the protein or by covalent coupling of radioactive metal complexes. These molecules combine a tumor seeking function and a radioactive function.

- 5 Although these types of molecules have been used for diagnosis, their use in therapy was not yet described.

It is the object of the present invention to further improve on the above described molecules to come to an even better tailored treatment of malignant cells.

- 10 This object is achieved by the invention by the provision of a molecule in which three functions are combined. This molecule comprises a tumor seeking molecule, which is coupled to an intercalating moiety, which is capable of complexing a metal, which metal is
15 preferably a radioactive metal. The molecule can be targeted specifically to the tumor by the tumor seeking molecule and be internalized by the cell. The intercalating moiety will then insert into the DNA strand and induce breaks. In addition, the radioactive metal
20 will also lead to strand breaking of the DNA. The advantage of the new molecules is that they are specifically directed to the malignant cell and are taken up by the cell.

- The tumor seeking molecule is preferably a
25 biomolecule, such as a peptide or protein that is actively targeted to the tumor cell. Examples of these biomolecules are somatostatin-, neurotensin-, bombesin-receptor binding molecules, monoclonal antibodies, penetratinesTM, and glycoproteins, and molecules binding
30 to the GPIIb/IIIa receptors. The invention is however not limited to these examples and is more generally applicable to other tumor seeking agents as well. This category encompasses in addition compounds which are known to be transported into the nucleus or the nucleus
35 membrane. Examples of these are anti-sense oligonucleotides, proliferating agents, like deoxy-uridine, and small molecules, like spermidine.

The intercalating moiety is preferably an aromatic molecule with an intercalative binding affinity

09913788-034504

for double-stranded DNA. Examples of such aromatic compounds are compounds containing i.e. acridine, porphyrin, ellipticine, phenantroline, carbazole, benzimidazole or compounds with known cytostatic activity (antibiotics) from the class of tetracyclines (anthracyclines), such as daunorubicine, epirubicine or mixoxantrone and are functionalized with ligands able to coordinate the $[M(CO)_3]^+$ moiety. Examples of such ligands are those mentioned in EP-879 606 and additionally polyamino-polycarboxylates, phosphates and phosphonates, aliphatic or aromatic or mixed triamines and thiones.

The intercalating and tumor seeking functions are sometimes combined in existing molecules. Examples of intercalating agents combining an intercalating moiety and a peptide are actinomycin and triostin.

The radioactive molecule can be any radioisotope. Pure γ -emitting nuclides are preferred since their accompanying low range conversion electrons will lead to cleavage of bonds, which are close to the decaying nucleus. The dose burden to the patient remains thus very low.

Particularly suitable combinations of the three functions are given in Fig. 1.

The invention further relates to the use of the molecules in therapy and diagnosis and to therapeutical and diagnostic compositions comprising one or more of these molecules.

Therapeutical compositions comprise at least a suitable amount of the molecule in a diluent or excipient. Such compositions can take the form of solutions and are administered intravenously, intraperitoneally or intrathecally. Suitable amounts to be administered depend on the way of administration, the radionuclide used and the indication to be treated or diagnosed. Suitable amounts vary between 10^{-9} and 10^{-1} g per kg body weight.

Excipients and diluents for this type of medication are well known to the skilled person. However,

the present molecules require certain conditions for stability. Preferably, the excipient or diluent should be of a hydrophilic and preferably organic nature.

For diagnostic purposes the composition
5 consists of at least a suitable amount of the molecule in a diluent or excipient. Diagnostic methods to be used with the composition of the invention are scintigraphy or Magnetic Resonance Imaging (MRI).

It was now found that the method for the
10 synthesis of Tc and Re carbonyls from water described in EP-879 606 is suitable for preparation of the molecules of the invention. It is in particular possible with this method to introduce intercalating ligands, which form very stable complexes (in vitro and in vivo) with the
15 above mentioned carbonyls. EP-879 606 is incorporated herein by reference.

The ligands claimed in EP-879 606 and acridine, porphyrin, ellipticine, phenantroline, carbazole, benzimidazole do stabilize the $\text{fac-[Tc(CO)}_3\text{]}^+$ moiety in
20 serum and form complexes at very low concentrations. These ligands can be site specifically attached to the biomolecules and subsequently be labeled with i.e. Tc-99m. Since the radionuclide is very close to the intercalating ligand, its low energy electron will penetrate the
25 DNA-strands very well and induce strandbreaking. When intercalating in one of the grooves, the probability to hit is very high since the nucleus is practically surrounded by DNA.

The biomolecules derivatized according to the
30 invention exhibit high selectivity and are internalized. As known from pure organic intercalators, the complex is going to intercalate in DNA in particular when the cell is dividing. In contrast with other therapeutics, a high selectivity can be achieved with this combination.

35 If Re-188 is applied as the radionuclide, the damages will be much more severe than in the case of Tc-99m, but, consequently, the applied amount of radioactivity will be much lower than in case of "normal"

TOP SECRET 0044660

radiotherapy. Thus, severe side effects such as bone marrow toxicity could be avoided.

The present invention will be further illustrated in the examples that follow and which are solely intended to clarify the invention, but are in no way intended to be limiting to the scope thereof.

In the Examples reference is made to the following figures:

Figure 1: schematic representation of potential molecules of the invention.

Figure 2: example of a Tc(I) complex with this intercalating ligand and a potential biomolecule attached by direct linkage to another coordination site.

Figure 3: schematic representation of the method for preparing molecules of the invention.

Figure 4: schematic representation of the three types of plasmid structures.

Figure 5: ethidium bromide stained agarose gel of the three types I, II and III of DNA (left lane) and a molecular weight marker (right lane).

Figure 6: ethidium bromide stained agarose gel of a plasmid preparation treated with the compound $[^{99m}\text{Tc}(\text{P}_1)(\text{teta})(\text{CO})_3]$; The application site of the sample is on the bottom of the gel. Lane 1 is the molecular weight marker; lane 2 is a reference solution containing supercoiled, relaxed (single strand break) and linearized (double strand break) plasmid, lane 3 is the experimental solution containing both plasmid and the intercalator of the invention, and lane 4 is the negative reference containing only plasmid.

Figure 7: reaction scheme for the preparation of model bifunctional intercalators.

Figure 8: reaction scheme for the preparation of model trifunctional intercalators.

09913788-081501

EXAMPLES

EXAMPLE 1

Synthesis of the molecules of the invention

1. Introduction

5 To provide a strong intercalation, the intercalator should be preferably planar and aromatic heterocyclic. Furthermore, pendant groups in the intercalator must stably be coordinated to the radionuclide (i.e. ^{99m}Tc). In this example, it is not
10 coercive that the coordinating unit must be a multidentate ligand with high thermodynamic stability, since most complexes with Tc(I) show an extremely high kinetic stability. For these reasons and due to the already known principles of complexation of several mono-
15 and bidentate ligands (especially picolinic acid) 5,6-benzochinolin-3-carboxylic acid was selected as intercalator.

Figure 2 depicts an example of a Tc(I) complex with this intercalating ligand and a potential
20 biomolecule attached by direct linkage to another coordination site.

2. Synthesis of the example intercalator

2.1. 3-cyano-4-benzoyl-3,4-dihydrobenzo(f)chinoline 2

25 648 μl (5.58 mmol) benzoyl chloride was added to a two phase system of water/methylene chloride over a period of two hours. These two layers contain 500 mg (2.79 mmol) of benzo(f)chinolin in the methylene chloride layer and 545 mg (8.37 mmol) KCN in water. Stirring was
30 continued for 6 hours. The organic phase was separated and washed with water, 5% hydrochloric acid, water, 5% NaOH solution, and again with water. After drying over magnesium sulfate, the solution was evaporated to dryness.

35 The bromide salt of this so-called Reissert-compound was recrystallized from 95% ethanol to yield the analytically pure substance. Yield: 612 mg (71%).

2.2 5,6-benzochinolin-3-carbon acid (P1)

2 ml 48% hydrobromide acid were added to 287 mg (0.93 mmol) of the Reissert-compound dissolved in 2 ml acetic acid. The solution was refluxed during 24 hours, cooled and filtered. The filtered product was washed with diethyl ether, dried, and recrystallized from methanol to yield 169 mg (0.76 mmol) (82%) of the hydrobromide of the intercalator as a yellow solid.

2.3 Macroscopic synthesis of Technetium and Rhenium complexes with P1 (5,6-benzochinolin-3-carbon acid)

2.3.1 $[\text{NEt}_4][\text{ReBr}(\text{P1})(\text{CO})_3]$

A suspension of 102 mg (133 μmol) $[\text{NEt}_4][\text{ReBr}_3(\text{CO})_3]$, 29.7 mg (133 μmol) P1 and 116 μl (226 mmol) of trioctylamine were refluxed in dichloromethane until a clear solution was achieved. After evaporation of the solution, the complex 5 was extracted into THF. After evaporization of THF the residue was washed with diethyl ether to remove trioctyl ammonium bromide. Yield: 63 mg (67%) of the yellow complex.

2.3.2 $[\text{Re}(\text{P}_1)(\text{H}_2\text{O})(\text{CO})_3]$

200.0 mg (0.26 μmol) of $[\text{NEt}_4]_2[\text{ReBr}_3(\text{CO})_3]$ were refluxed in the presence of 29.1 mg of the intercalator P1 during 4 hours in 1M MES-buffer solution. Then the yellow precipitation was filtered. Yield: 114.2 mg (86%).

2.4 Microscopic synthesis of $[\text{}^{99\text{m}}\text{Tc}(\text{H}_2\text{O})(\text{P}_1)(\text{CO})_3]$

The $^{99\text{m}}\text{Tc}$ complexes were synthesized in a two-step procedure with a normal generator eluate. In a first step the complex was synthesized in >97% yield according to the literature (R. Alberto et al., J. Am. Chem. Soc. 120, 7987 (1998)). The solution was then neutralized with phosphate buffer in the reaction vial and a solution of the corresponding ligand was added. The end concentration was between 10^{-4} and 10^{-5} . It was left standing for 30 minutes at 75°C. The radio-chemical purification and the yield were defined through HPLC-

chromatography and it was discovered that $[^{99m}\text{Tc}(\text{HPO}_4)(\text{P}_1)(\text{CO})_3]^{2-}$ (compound 10) with a yield of 80-95% (dependent on the ligand concentration and the reaction time) was formed.

5

2.5 Synthesis of model trifunctional molecules of the invention


This is an example how a trifunctional molecule can be built. The procedure is based on known synthetic approaches for the corresponding coupling methods. The schematic procedure is given in Figure 3.

1. Syntheses of the bifunctional ligands, bearing an intercalator and a coordinating functionality

A bifunctional ligand was prepared according to the strategy described in Fig. 3. Fig. 7 gives the specific reaction scheme of the reaction that is described hereinbelow.

20

25



2-Methylquinoline (1)

2-Methylquinoline (1) was bought from Fluka and used without further purification.

Quinoline-2-carbaldehyde (2)

A mixture of 5.5 g of selenium dioxide (49.5 mmol) in 50 ml dioxane and 2 ml water was added in small portions over 10 minutes to a boiling solution of 4.4 g (30.7 mmol) of 2-methylquinoline (1) in 20 ml dioxane. After 6 hours of boiling, the warm reaction mixture was filtered. The filtrate was evaporated, dissolved in

dichloromethane and filtered through Alox. The yellow-brown solid product obtained after evaporation of the solvent was recrystallized from dichloromethane. Yield: 3.76 g (78%)

5 $^1\text{H-NMR}$ (DMSO): δ , 10.12s, 8.61d, 8.22d, 8.12d, 7.99d, 7.91t, 7.79t

Compound 3a

A mixture of 500 mg of quinoline-2-carbaldehyde
10 (2) (3.2 mmol) and 330mg of N-(2-aminoethyl)-acetamid (3.23 mmol) in 15 ml of methanol was stirred for 2 hours at room temperature. The light brown solid product obtained was directly used for the next reaction. Yield: ~770 mg (~100%)

15 $^1\text{H-NMR}$ (CDCl_3): δ , 8.57s, 8.21d, 8.13d, 8.10d, 7.85d, 7.75t, 7.59t

Compound 3b

A solution of 175 mg (4.62 mmol) of NaBH_4 in 10
20 ml of ethanol was slowly added over 2 hours to a stirred solution of 500 mg (2.07mmol) of 3a in 30 ml ethanol at 0°C. This mixture was then stirred overnight at room temperature. The solid substance obtained after evaporation of the solvent was triturated with a 3M Na_2CO_3
25 solution. The desired light brown product (3b) was then extracted with dichloromethane. Yield: 382 mg (76%)

$^1\text{H-NMR}$ (CDCl_3): δ , 8.15d, 8.05d, 7.81d, 7.71t, 7.54t, 7.35d, 6.84br, 4.21s, 3.50q, 3.02t, 2.02s

30 Compound 3c

A solution of 200 mg of 3b (0.82 mmol) in 20 ml of 2N HCl was refluxed for 6 hours. The oil obtained after evaporation of the solvent was washed with ethanol to give the desired light brown solid hydrochloride salt

35 3c. Yield: 203 mg (90%)

$^1\text{H-NMR}$ (D_2O): δ , 8.40d, 7.95t, 7.76t, 7.59t, 7.49d, 4.57s, 3.46t, 3.34t

09913755-004501

N-BOC-diethylentriamine (4)

A solution of 500mg (2.29 mmol) of di-tert-butyl dicarbonate ((BOC)₂O) in 30 ml dioxan was slowly added to a solution of 1.49 ml (1.42 g) (13.74 mmol) of diethylentriamine in 80 ml of dioxan at 10°C. The mixture was then stirred for 15 hours at room temperature. The desired product precipitated as an oil, which was then separated from the rest of the solution, dissolved in water, filtered, and extracted with dichloromethane to finally give the desired product as a light yellow oil. Yield: 260 mg (56%)
¹H-NMR (CDCl₃): δ, 5.15br, 3.25br, 3.18t, 2.77t, 2.69t, 2.63t, 1.76br, 1.41s, 1.19t

Compound 5a

A mixture of 140 mg of quinoline-2-carbaldehyde (2) (0.89 mmol) and 200mg of N-BOC-diethylentriamine (0.99 mmol) in 30 ml of methanol was stirred for 3 hours at room temperature. The solid obtained after evaporation of the solvent was then washed with water to obtain the desired light brown product. Yield: 304 mg (94%)
¹H-NMR (DMSO): δ, 8.32d, 7.97t, 7.73t, 7.71d, 7.57t, 6.65t, 4.33s, 3.08t, 2.97t, 2.85t, 1.28s, 1.09t

Compound 5b


A solution of 41 mg (1.08 mmol) of NaBH₄ in 10 ml of ethanol was slowly added over 2 hours to a stirred solution of 148 mg (0.43mmol) 5a in 30 ml of ethanol at 0°C. This mixture was then stirred overnight at room temperature. The solid brown oil obtained after evaporation of the solvent was triturated with a 3M Na₂CO₃ solution. The desired light brown product (3b) was then extracted with dichloromethane. Yield: 136 mg (92%)
¹H-NMR (DMSO): δ, 8.29d, 7.94d, 7.92d, 7.71t, 7.61d, 7.54t, 6.71t, 3.95s, 2.96q, 2.59s, 1.33s, 1.22t

Compound 5c

A solution of 100 mg of **5b** (0.29 mmol) in 3N HCl was refluxed for 2 hours. The oil obtained after evaporation of the solvent was washed with diethylether to give the desired light brown solid hydrochloride salt **5c**. Yield: 102 mg (94%)
 $^1\text{H-NMR}$ (D_2O): δ , 8.44d, 7.95t, 7.77t, 7.6t, 7.51d, 4.51s, 3.44s, 3.34t, 3.27t

2. Synthesis of trifunctional model intercalators

Trifunctional intercalators were prepared starting from **5a** or **3b** of part 1 above. Fig. 8 gives the specific reaction scheme.

**1. alkylation of an amine with bromo-aceticacid-ethylester**

25 Amine I (Fig. 7; 547 mg, 2.83 mmol) and triethylene amine (0.510 ml, 3.08 mmol) were stirred in methanol (10 ml). The solution was cooled to 0°C, and ethyl bromoacetate II (0.313 ml, 2.83 mmol) was added dropwise within 5 minutes. After stirring the solution at
30 room temperature for 18 hours, the solvent was removed in vacuo. The residue was dissolved in dichloromethane (50 ml) and washed three times with water (20 ml). The water phases were washed twice with dichloromethane (50 ml). The organic phases were dried over MgSO_4 , filtered, and
35 the solvent was removed in vacuo to give III as a yellow oil. Yield: 590 mg (2.11 mmol, 74.6%).
TLC (silica, ethanol) R_f 0.4

¹H NMR (200 MHz, d₆-acetone) δ = 8.44 (m, 1H, picolin), 7.65 (m, 1H, picolin), 7.45 (m, 1H, picolin), 7.21 (m, 1H, picolin), 4.12 (q, 2 H, J = 7.2 Hz, CH₂ ester), 3.94 (s, 2H, CH₂), 3.64 (s, 2H, CH₂), 3.32 (m, 2H, N-CH₂-CH₂-N), 2.82 (m, 2H, N-CH₂-CH₂-N), 1.84 (s, 3H, CH₃-CO), 1.21 (t, 3H, J = 7.2 Hz, CH₃ ester).

2. deprotection

Amine III (576 mg, 1.94 mmol) was dissolved ethanol (4 ml) and water (8 ml). NaOH 2M (2 ml) was added, and the solution was stirred at room temperature for 1.5 hours. Analytical HPLC exhibited a single peak, indicating that the ester group was cleaved quantitatively.

The solvent was removed in vacuo, the residue was dissolved in water (8 ml), and HCl 2N (1 ml) was added to neutralize the solution. HCl 33% (1.0 ml) was added, and the reaction mixture was stirred at 90°C for 48 hours. NaHCO₃ was added to neutralize the reaction mixture, the solvent was removed in vacuo and the residue was washed with ethanol. Removing of the solvent gave the deprotected product V as a yellow oil. Yield: 352 mmol (1.68 mmol, 68.6%).

¹H NMR (300 MHz, D₂O) δ = 8.44 (m, 1H, picolin), 7.85 (m, 1H, picolin), 7.45 (m, 1H, picolin), 7.39 (m, 1H, picolin), 3.78 (s, 2H, CH₂), 3.35 (m, 2H, N-CH₂-CH₂-N), 3.22 (s, 2H, CH₂), 3.32), 2.79 (m, 2H, N-CH₂-CH₂-N).

30 **EXAMPLE 2**

Strand breaking with the molecules of the invention in a model system

1. **Introduction**

1.1 The use of plasmids

To investigate the ability of the intercalating complexes with ^{99m}Tc to induce DNA-strandbreaks, plasmids were used as a model system. Plasmids are very suitable because electrophoretic analyses allow to differentiate

between double and single strand breaks. Additionally, large quantities of plasmids can be produced very simply by using cell biological methods.

A plasmid is a circular double-stranded DNA molecule, which double helical axis can be drilled into a superhelix. This form of the superhelix is described as type I. This type may lose its superhelix-structure by a single strandbreak and is then present as a relaxed circular DNA (type II). Through a double strandbreak of both types a linear form (type III) of the plasmid will be created. Figure 4 shows an example of the structure of these 3 DNA types.

Because these three DNA types have different structures, they may well be separated due to their size and especially their form by electrophoresis on agarose gel. The mixture (type I-III after the experiment) to be investigated is loaded on an agarose gel. A constant voltage will then be applied and the negatively charged DNA-fragments will migrate toward the cathode. The larger the form of the fragment, the slower the migration along the gel. DNA of type I (most compact) moves fastest, type II slowest. The gel will then be put in solution which contains very little ethidium bromide. The DNA fragments are made visible by intercalation and irradiation with UV-light of 300 nm depicting red-orange colored fluorescence (590 nm). This method is so sensitive that less than 5 ng DNA per band are detected. In the photographic record of the gels in Figure 5, the migration direction is from the top to the bottom.

1.2 Production of the plasmids

The plasmid Bluescript KSTM with a size of 2958 base pairs has been produced following the standard protocol of the company QIAGEN. Usually, this plasmid exists in the superhelix form (type I). With the restriction enzyme KpnI the linearized form of the plasmid DNA (type III) can be produced. A single strandbreak resulting in the relaxed circular form of

09913788-081501

plasmid (type II), can be induced by the enzyme DNAase I. Figure 5, right lane, shows the electrophoresis on agarose-gel of a mixture of these three types of DNA. For the electrophoresis a marker with several sizes of DNA-
5 pieces has been used as reference (left lane).

As demonstrated by the three bands of the right lane, the three types of DNA were clearly separated and can be distinguished after visualization. If single or double strand breaks result from conversion electrons, it
10 should be easy detectable by this method.

2. Investigation of the ability of $[^{99m}\text{Tc}(\text{P}_1)(\text{teta})(\text{CO})_3]$ to induce strandbreaks

5 μl of a solution containing approx. 0.3 mCi/
15 ml of $[^{99m}\text{Tc}(\text{P}_1)(\text{teta})(\text{CO})_3]$ and 100 ng of type I plasmid ($\sim 3 \cdot 10^5$ M in base pairs) were left standing over a period of 18 hours. Then a electrophoresis of this mixture and the three references was made (Figure 6).

It is clearly visible that the plasmids in the
20 measurement solution (lane 3) migrate slower than in the reference solution. The reason for this observation is that a small change in the structure of the plasmids is probably induced by intercalation of the complex into the double strand. This change in the tertiary structure of
25 the plasmid did then allow a better intercalation of the ethidium bromide, thus explaining the stronger intensity of the band of sample solution.

Furthermore, in the comparison with the negative reference solution (lane 4), it is obvious that
30 one or possibly two new bands appeared (arrows) in the lane of the solution treated with the ^{99m}Tc complex. The stronger of these two bands corresponds approximately to the position of type II on the band of reference solution in lane 2, containing the three types. This means that
35 the complex has induced a single strand break in the plasmid.

09913788 081501
TESTED "081501"

ART 34 AMDT

Enclosure to letter dated 10 April 2001
International application No. PCT/EP00/01553

11.04.2001

NEW CLAIMS

(100)

1. Use of molecules that are taken up by the cell, which molecules comprise a tumor seeking biomolecule coupled to an intercalating moiety, which is complexed to a metal, which metal is preferably a radioactive metal, for the preparation of a therapeutical composition for the treatment and diagnosis of tumors and malignancies.

2. Use as claimed in claim 1 wherein the biomolecule is selected from the group consisting of somatostatin-, neurotensin-, bombesin-receptor binding molecules, antibodies, penetratinesTM, and molecules binding to the GPIIb/IIIa receptors.

3. Use as claimed in claims 1 and 2 wherein the intercalating agent is an aromatic molecule with an intercalative binding affinity for double-stranded DNA.

4. Use as claimed in claim 3, wherein the intercalating agent is selected from the group consisting of acridine, porphyrin, ellipticine, phenantroline, carbazole, benzimidazole or compounds with known cytostatic activity (antibiotics) from the class of tetracyclines (anthracyclines), such as daunorubicine, epirubicine or mixoxantrone.


5. Use as claimed in claims 1-4, wherein the radioactive metal is a γ -emitting nuclide.

6. Use as claimed in claim 5, wherein the radioactive metal is selected from the group consisting of Tc-99m, Re-186, Re-188 and Mn.


7. Use as claimed in claims 1-6, wherein the molecule has the general structural formula as given in Fig. 2.





8. Use as claimed in claims 1-7, wherein the molecule has any one of the structures as shown in Fig. 1.

1/7



2/7

FIG. 2

**FIG. 3**




FIG. 4

5/7




FIG. 6



FIG. 5

6/7

Reaction Scheme




FIG. 7

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)	Attorney Docket Number	1292 WO/US
	First Named Inventor	ALBERTO, Roger
	COMPLETE IF KNOWN	
	Application Number	/
	Filing Date	
	Group Art Unit	
<input checked="" type="checkbox"/> Declaration Submitted with Initial Filing OR <input type="checkbox"/> Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)		Examiner Name

As a below named inventor, I hereby declare that:

My residence, mailing address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

COMBINATION OF INTERCALATING ORGANOMETALLIC COMPLEXES
AND TUMOR SEEKING BIOMOLECULES FOR DNA CLEAVAGE AND
RADIO THERAPY

(Title of the Invention)

the specification of which

☐ is attached hereto

OR

☒ was filed on (MM/DD/YYYY) 02/24/2000 as United States Application Number or PCT International

Application Number EP00/01553 and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
60/121340	USA Prov.	02/24/1999	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
99200754.2	EP	03/12/1999	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 21 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Appointment of Agent

The undersigned applicant hereby appoints:

Lawrence L. Limpus Reg. No. 27,816

Jeffrey S. Boone Reg. No. 29,284

all of:

Mallinckrodt Inc.
675 McDonnell Boulevard
St. Louis, Missouri 63042
United States of America
Telephone Number: 314.654.3778
Facsimile Number: 314.654.3156

as agents to act on its behalf before the competent International Authorities in connection with any and all international applications filed by it and to receive payments on its behalf.

At: St. Louis, Missouri, United States of America

Date: 31 MARCH 1999

Mallinckrodt Inc.




Lawrence L. Limpus

Assistant Secretary

09913788-081501
FOSTER 8847660

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent Application

Direct all correspondence to: <input type="checkbox"/>		Customer Number or Bar Code Label	<input type="checkbox"/>		OR <input checked="" type="checkbox"/> Correspondence address below
Name <u>Jeffrey S. Boone</u>					
Address <u>675 McDonnell Boulevard, P.O. Box 5840</u>					
City <u>St. Louis</u>		State <u>MO</u>		ZIP <u>63134</u>	
Country <u>USA</u>		Telephone <u>314-654-8955</u>		Fax <u>314-654-3156</u>	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.					
NAME OF SOLE OR FIRST INVENTOR :			<input type="checkbox"/> A petition has been filed for this unsigned inventor		
Given Name (first and middle [if any]) <u>Roger Ariel</u>			Family Name or Surname <u>ALBERTO</u>		
Inventor's Signature 			Date <u>20.7.01</u>		
Residence: City <u>Winterthur</u>		State		Country <u>Switzerland</u>	Citizenship <u>Switzerland</u> CHX
Mailing Address <u>St. Georgenstrasse 54</u>					
City <u>Winterthur</u>		State		ZIP <u>CH-8400</u>	Country <u>Switzerland</u>
NAME OF SECOND INVENTOR:			<input type="checkbox"/> A petition has been filed for this unsigned inventor		
Given Name (first and middle [if any]) <u>Pascal Jean-Marie</u>			Family Name or Surname <u>HAFLIGER</u>		
Inventor's Signature			Date		
Residence: City <u>Zurich</u>		State		Country <u>Switzerland</u>	Citizenship <u>Switzerland</u>
Mailing Address <u>Guggacherstrasse 42</u>					
City <u>Zurich</u>		State		ZIP <u>CH-8006</u>	Country <u>Switzerland</u>
<input type="checkbox"/> Additional inventors are being named on the _____ supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.					

**DECLARATION FOR UTILITY OR
DESIGN
PATENT APPLICATION
(37 CFR 1.63)**

☒ Declaration Submitted with Initial Filing **OR** ☐ Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)

Attorney Docket Number	1292 WO/US
First Named Inventor	ALBERTO, Roger
COMPLETE IF KNOWN	
Application Number	/
Filing Date	
Group Art Unit	
Examiner Name	

As a below named inventor, I hereby declare that:

My residence, mailing address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

COMBINATION OF INTERCALATING ORGANOMETALLIC COMPLEXES
AND TUMOR SEEKING BIOMOLECULES FOR DNA CLEAVAGE AND
RADIO THERAPY

(Title of the Invention)

the specification of which

☐ is attached hereto

OR

☒ was filed on (MM/DD/YYYY) 02/24/2000

as United States Application Number or PCT International

Application Number EP00/01553 and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed.

application on which priority is claimed.					
Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
60/121340 99200754.2	USA Prov. EP	02/24/1999 03/12/1999	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/> Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:					

[Page 1 of 2]

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent Application

Direct all correspondence to: ☐ Customer Number or Bar Code Label OR ☒ Correspondence address below

Name Jeffrey S. Boone

Address 675 McDonnell Boulevard, P.O. Box 5840

City St. Louis State MO ZIP 63134

Country USA Telephone 314-654-8955 Fax 314-654-3156

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NAME OF SOLE OR FIRST INVENTOR: ☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any]) Roger Ariel

Family Name or Surname ALBERTO

Inventor's Signature

Date

Residence: City Winterthur

State

Switzerland Switzerland
Country Citizenship

Mailing Address St. Georgenstrasse 54

City Winterthur

State

CH-8400 Switzerland
ZIP Country

NAME OF SECOND INVENTOR: ☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any]) Pascal Jean-Marie

Family Name or Surname HAFLIGER

Inventor's Signature

Date 300701

Residence: City Zurich

State

Switzerland Switzerland
Country Citizenship

Mailing Address Guggacherstrasse 42

City Zurich

State

CH-8006 Switzerland
ZIP Country

☐ Additional inventors are being named on the _____ supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.